Valuation: Attovia Therapeutics, Inc.

Market Cap 1.01B 881M 830M 756M 1.42B 96.83B 1.42B 9.94B 3.83B 49.33B 3.8B 3.71B 159B P/E 2026 *
-7.97x
P/E 2027 * -10.6x
Enterprise Value 632M 551M 519M 472M 886M 60.52B 887M 6.21B 2.39B 30.83B 2.37B 2.32B 99.49B EV / Sales 2026 *
1,354x
EV / Sales 2027 * -
Free-Float
91.15%
Yield 2026 *
-
Yield 2027 * -
1 day-5.83%
1 week-14.46%
Current month-1.99%
1 month+0.84%
1 week 20.21
Extreme 20.21
25.46
1 month 18.85
Extreme 18.85
28
Current year 16.15
Extreme 16.1501
28
1 year 16.15
Extreme 16.1501
28
3 years 16.15
Extreme 16.1501
28
5 years 16.15
Extreme 16.1501
28
10 years 16.15
Extreme 16.1501
28
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 16/12/2022
Chief Tech/Sci/R&D Officer 61 01/06/2023
Chief Executive Officer 54 01/04/2023
Director TitleAgeSince
Director/Board Member 42 01/06/2023
Director/Board Member 54 01/04/2023
Chairman 64 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
6/8/26
Goldman Sachs & Co. LLC (Private Banking)
ConversionCompany 25,562,737 59.4081%
6/8/26 Conversion 1,865,710 4.3359%
6/8/26
Deep Track Capital LP
ConversionCompany 20,138,956 46.8032%
Change 5-day change 1-year change 3-year change Capi.($)
-5.83%-14.46% - - 1.01B
+4.98%+11.06%+54.45%+109.45% 70.88B
-0.39%+0.02%+37.52%+83.28% 62.49B
+5.26%+12.77%+40.29%+26.34% 26.34B
+2.37%-2.08%-15.40%+365.81% 26.21B
+2.10%-1.24%-1.10%-8.27% 24.13B
0.00%+6.81%+24.48%-11.44% 20.72B
-2.54%-10.16%+149.64%+313.93% 15.69B
-1.92%+1.60%+44.29%+164.64% 14.46B
-5.91%-8.88%-12.12%+817.21% 14.24B
Average -0.19%+1.48%+35.78%+206.77% 27.62B
Weighted average by Cap. +1.53%+2.88%+36.92%+151.73%

Financials

2026 *2027 *
Net sales 467K 407K 383K 349K 654K 44.71M 655K 4.59M 1.77M 22.77M 1.75M 1.71M 73.49M -
Net income -83.44M -72.75M -68.52M -62.4M -117M -7.99B -117M -821M -316M -4.07B -313M -306M -13.14B -107M -93.42M -87.99M -80.13M -150M -10.26B -150M -1.05B -406M -5.23B -402M -394M -16.87B
Net Debt -379M -330M -311M -283M -531M -36.31B -532M -3.73B -1.44B -18.49B -1.42B -1.39B -59.68B -286M -249M -235M -214M -401M -27.41B -402M -2.81B -1.08B -13.96B -1.07B -1.05B -45.06B
Logo Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.
Employees
44
Date Price Change Volume
22/09/26 USD 20.98 -5.26% 105,324
18/09/26 USD 22.14 -2.60% 1,361,381
17/09/26 USD 22.73 +2.16% 292,607
16/09/26 USD 22.25 -6.12% 293,373
15/09/26 USD 23.70 -3.34% 198,402
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
22.14USD
Average target price
42.20USD
Spread / Average Target
+90.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATTO Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!